Glutathione: injection, IV or oral?
Compare what each route involves without assuming that delivering more of a molecule proves a better clinical result.
The short answer
Route changes convenience and administration. The cited clinical evidence does not establish which route improves general energy or recovery, and a trial in a specific disease population cannot answer that question for everyone.
Side by side
| Injection | IV infusion | Oral | |
|---|---|---|---|
| Administration | Injection as prescribed | Infusion through an IV | Swallowed product |
| What to compare | Formulation, technique and treatment goal | Clinical setting, formulation and treatment goal | Ingredients, formulation and treatment goal |
| Evidence needed | Relevant patient outcomes | Relevant patient outcomes | Relevant patient outcomes |
What the evidence shows
One randomized intranasal glutathione trial in Parkinson disease found no superiority over placebo for its active groups. It studied none of the three routes in this table and does not establish a general wellness benefit. It illustrates why route and population must stay attached to a claim.
Read: Mischley et al. Intranasal glutathione in Parkinson disease; FDA: Compounding questions and answers.
What matters for your decision
Ask which study supports your proposed route and goal. Account for administration burden and the entire course cost. A rise in a marker does not by itself tell you whether treatment is worth continuing.
Questions
Does AnthologyRX offer every route in this comparison?
No. This is an evidence and route comparison, not a claim that every format is available here. Current treatment pages show the offered preparations.
Sources
- Mischley et al. Intranasal glutathione in Parkinson disease
Journal of Parkinson’s Disease, 2017. Phase IIb trial; active groups not superior to placebo.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
